Therefore, the possibility to avoid the use of immunotherapy in patients with LKB1-inactive NSCLC, while promoting experimental studies aimed at evaluating new treatment strategies, should be preferred in this clinical context. This evidence concerns the gene STK11 and non-small cell lung carcinoma.